United States Brain Tumor Market Size, Share, and COVID-19 Impact Analysis, By Tumor Type (Malignant and Non-Malignant), By Treatment Type (Interventional Device-Based Procedures, Chemotherapy, Radiation Therapy, Surgery, and Others), and U.S. Brain Tumor Market Insights, Industry Trend, Forecasts to 2033.

U.S. Brain Tumor Market Insights Forecasts to 2033

• The United States Brain Tumor Market Size Was Estimated at USD 1.62 Billion in 2023.
• The Market Size is Growing at a CAGR of 9.49% from 2023 to 2033
• The USA Brain Tumor Market Size is Expected to Reach USD 4.01 Billion by 2033

The US Brain Tumor Market Size is Expected to reach USD 4.01 Billion by 2033, Growing at a CAGR of 9.49% from 2023 to 2033

Market Overview

In the United States, the market for brain tumors is the medical field that deals with brain tumor diagnosis, treatment, and management. Primary (originating in the brain) and secondary (metastasizing from other bodily areas) brain tumors are the two types. Products in the market include surgical procedures, radiation, chemotherapy, diagnostic tools (such as imaging equipment), and cutting-edge therapies including immunotherapy and targeted therapy. The rising incidence of brain cancer and the growing number of brain tumor diagnoses in the United States are the primary drivers of the growth. The market is growing due to rising governmental and private sector funding and investments. For instance, GammaTile, a radiation therapy solution for patients with operable brain tumors, has been expanded in the U.S. market by GT Medical Technologies, Inc., which announced that it has raised USD 37 million in a series D financing round. The funds will support GammaTile's strategic initiatives for clinical and commercial expansion. The funding will assist programs aimed at expanding access to care for patients with severe meningiomas, brain metastases, and high-grade gliomas.

Report Coverage

This research report categorizes the market for the U.S. brain tumor market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the US brain tumor market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the USA brain tumor market. 

Driving Factors

The market is expanding due in large part to ongoing innovation in treatment alternatives, including as immunotherapies, targeted medicines, and improvements in surgical procedures. In addition, robotic surgery, targeted radiation therapy, and MRI are examples of innovative diagnostic and therapeutic technologies that are increasing treatment results and survival rates. Additionally, the treatment of brain tumors is being advanced by large investments in research and development for the creation of novel medications and treatments. It is anticipated that developments in targeted therapeutics and immunotherapy will further expand the industry.

Restraining Factors

The USA brain tumor market faces challenges due to the cost of treating brain tumors, which can be high and includes advanced medicines, radiation, and surgery.  This can put a financial strain on healthcare systems and prevent some groups from accessing treatment. In addition, the lengthy and expensive approval process for novel treatments and medications can prevent patients from receiving potentially life-saving treatments.

Market Segmentation

The U.S. brain tumor market share is classified into the tumor type and treatment type.

• The malignant segment accounted for the largest share of 62.39% in 2023 and is expected to grow at a significant CAGR during the forecast period.

Based on the tumor type, the U.S. brain tumor market is divided into malignant and non-malignant. Among these, the malignant segment accounted for the largest share of 62.39% in 2023 and is expected to grow at a significant CAGR during the forecast period. This segment is driven by an increase in glioblastoma and high-grade malignant brain tumors, as well as an increase in the prevalence of brain cancer. In addition, these tumors have a greater death rate, which has prompted improvements in medical technology and more financing for the development of new treatments.

• The surgery segment accounted for the highest share in 2023 and is expected to grow at a significant CAGR during the projected timeframe.

Based on the treatment type, the U.S. brain tumor market is divided into interventional device-based procedures, chemotherapy, radiation therapy, surgery, and others. Among these, the surgery segment accounted for the highest share in 2023 and is expected to grow at a significant CAGR during the projected timeframe. This segment is growing due to the most common method of treating many kinds of brain tumors, especially malignant types such as glioblastomas, is still surgery. In addition, technological and surgical advancements have increased the safety, efficacy, and patient confidence of brain procedures, resulting in better prognoses and faster recovery periods.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the U.S. brain tumor market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• GT Medical Technologies, Inc.
• Novocure
• ZAP Surgical Systems, Inc.
• Koninklijke Philips N.V.
• IBA Worldwide
• Aesculap, Inc. - a B. Braun company
• Accuray Incorporated
• Carthera
• Alpheus Medical Inc.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development

• In September 2024, Stryker declared the successful completion of its acquisition of NICO Corporation, a private company that specializes in cutting-edge, minimally invasive surgical treatments for the treatment of tumors and the control of intracerebral hemorrhage (ICH). Stryker's commitment to developing neurotechnology, particularly in the fields of tumor and stroke care, is demonstrated by this strategic purchase, which broadens its line of innovative products.

Market Segment

This study forecasts revenue at U.S., regional, and country levels from 2020 to 2033. Spherical Insights has segmented the U.S. brain tumor market based on the below-mentioned segments:

U.S. Brain Tumor Market, By Tumor Type

• Malignant
• Non-Malignant

U.S. Brain Tumor Market, By Treatment Type

• Interventional Device-Based Procedures
• Chemotherapy
• Radiation Therapy
• Surgery
• Others